S&P ASX All Technology

US Dollar vs AUD

Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.

Get Started

PASG Passage Bio Inc

0.6666

-0.0844 (-11.24%)

After Hours

Last Updated: 08:00:04

Delayed by 15 minutes

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Article too big to display. Click here to view on the SEC website

Passage Bio (NASDAQ:PASG)
Historical Stock Chart
From Oct 2024 to Nov 2024

Click Here for more Passage Bio Charts.

Passage Bio (NASDAQ:PASG)
Historical Stock Chart
From Nov 2023 to Nov 2024

Click Here for more Passage Bio Charts.

Passage Bio Inc News

Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
Friday 15 November 2024 (2 weeks ago) • Edgar (US Regulatory)

Form SC 13G - Statement of Beneficial Ownership by Certain Investors
Friday 15 November 2024 (2 weeks ago) • Edgar (US Regulatory)

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Wednesday 13 November 2024 (2 weeks ago) • Edgar (US Regulatory)

Form 8-K - Current report
Wednesday 13 November 2024 (2 weeks ago) • Edgar (US Regulatory)

Passage Bio Reports Third Quarter 2024 Financial Results and Provides Recent Business Highlights
Wednesday 13 November 2024 (2 weeks ago) • GlobeNewswire Inc.

Passage Bio to Present at Guggenheim Securities Healthcare Innovation Conference
Wednesday 6 November 2024 (3 weeks ago) • GlobeNewswire Inc.

Form 8-K - Current report
Thursday 24 October 2024 (1 month ago) • Edgar (US Regulatory)

Passage Bio Presents Preclinical and Interim Clinical Data for PBFT02 in FTD-GRN at the European Society of Gene & Cell Therapy (ESGCT) 31st Annual Conference
Thursday 24 October 2024 (1 month ago) • GlobeNewswire Inc.

Form 4 - Statement of changes in beneficial ownership of securities
Thursday 3 October 2024 (2 months ago) • Edgar (US Regulatory)

Passage Bio to Present at Chardan’s 8th Annual Genetic Medicines Conference
Monday 23 September 2024 (2 months ago) • GlobeNewswire Inc.

Form 8-K - Current report
Monday 16 September 2024 (2 months ago) • Edgar (US Regulatory)

Passage Bio to Present Positive Interim Data from Cohort 1 Patients with FTD-GRN in upliFT-D Study at 14th International Conference on Frontotemporal Dementias (ISFTD2024)
Monday 16 September 2024 (2 months ago) • GlobeNewswire Inc.

More Passage Bio Inc News Articles

Commonwealth Bank Of Aus...

Newcrest Mining

Australian SE All Ordina...

Gold vs US Dollar

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions